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ABSTRACT: The 2008–2013 World Health Organization (WHO) action plan on noncommunicable
diseases (NCDs) includes chronic respiratory diseases as one of its four priorities. Major chronic
respiratory diseases (CRDs) include asthma and rhinitis, chronic obstructive pulmonary disease,
occupational lung diseases, sleep-disordered breathing, pulmonary hypertension, bronchiectiasis
and pulmonary interstitial diseases. A billion people suffer from chronic respiratory diseases, the
majority being in developing countries. CRDs have major adverse effects on the life and disability of
patients. Effective intervention plans can prevent and control CRDs, thus reducing morbidity and
mortality. A prioritised research agenda should encapsulate all of these considerations in the frame
of the global fight against NCDs. This requires both CRD-targeted interventions and transverse
NCD programmes which include CRDs, with emphasis on health promotion and disease prevention.
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M
ajor chronic respiratory diseases (CRDs)
include asthma and rhinitis, chronic
obstructive pulmonary disease (COPD),
occupational lung diseases, sleep-disordered breath-
ing (SDB), pulmonary hypertension, bronchiectiasis
and pulmonary interstitial diseases [1].
Over 1 billion people of all ages suffer from CRDs
(table 1). Over 500 million of these live in low-
and middle-income countries (LMICs). CRDs are
increasing in prevalence and severity [1].
CRDs have major adverse effects on the life and
disability of patients [1]. It is estimated that 4
million people died prematurely from CRDs in
2005 and it is projected that, globally, the CRD
death rate and burden will considerably increase
in the future [2].
Everyone in the world is exposed to CRD risk
factors, and effective preventive measures are
available to reduce the deleterious impact of CRD
risk factors: tobacco smoking in all countries,
indoor air pollution and particularly biomass fuel
combustion in LMICs, outdoor air pollution,
unhealthy diet, lack of physical activity and obesity,
allergens, and occupational agents [1, 3, 4]. The
consequences of these factors start before birth and
continue throughout life [5–7]. Many of them
are common to other noncommunicable diseases
(NCDs) [2]. Furthermore, in some countries, infec-
tious diseases (including tuberculosis and HIV/
AIDS) add to the burden of CRD morbidity. Effec-
tive interventions can control CRD and reduce
morbidity and mortality.
Most CRDs occur in LMICs, which requires con-
sideration of the following factors. 1) Data on
CRD burden and risk factors are scarce and sur-
veillance of CRDs is unavailable in most LMICs.
Consequently, the true CRD burden on health
services and society is unknown. 2) Infrastructure
and programmes for the management of CRDs in
many LIMCs are not available or poorly devel-
oped because of competing priorities. Resources
are limited and fragmented. 3) Facilities for diag-
nosis and monitoring as well as essential medi-
cines for treating CRDs are not available and/or
affordable in many LMICs [8, 9]. 4) Strategies for
CRD prevention and health promotion are often
absent or rudimentary. 5) Programmes for educat-
ing healthcare providers (HCPs) in the care and
management of patients with CRDs require
strengthening. 6) Patient involvement in health
promotion programmes is rare or non-existent. A
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prioritised research agenda should encapsulate all of these
considerations in the frame of the global fight against NCDs.
This requires both CRD-targeted interventions, and transverse
NCD programmes that address CRDs and health promotion to
prevent them.
Among the CRDs, there are currently four major topics for
which more research is needed: 1) severe/uncontrolled asthma
and comorbidities; 2) COPD and comorbidities; 3) SDB, links
with obesity and other NCDs; and 4) early determinants of
respiratory diseases.
REVIEW OF SUCCESSFUL INTERVENTIONS
Asthma
Successful interventions in developed countries
The implementation of clinical practice guidelines has led to
improvements in the quality of care and reductions in the
burden of disease [10, 11]. Patient education improves asthma
control, reduces urgent care visits and improves quality of life
[12, 13]. Environmental control may improve asthma control
[14] but single intervention measures are not effective [15].
Successful interventions in LMICs
Outdoor air pollution may be controlled, thus reducing asthma
severity [16]. For LMICs, The International Union Against
Tuberculosis and Lung Disease has developed a guide for
asthma management focusing on the World Health Organi-
zation (WHO) list of essential medicines [17]. A study in a
limited number of patients in LMICs has shown benefits [18]
and a systematic approach to the organisation of standard case
management has been proposed [19].
Community-wide programmes
There are limited data on the effectiveness of asthma care in
whole populations at the community level. However, there was
a considerable cost-effective reduction of hospitalisations and
deaths in a study from Finland [20]. In middle-income countries
and deprived populations, availability of effective drugs and
education reduced hospitalisations and was cost-effective [21–23].
COPD and comorbidities
Successful interventions in developed countries
Several guidelines are available for COPD management [24, 25].
However, they should be adapted for LMICs [26]. Environ-
mental control is essential, in particular for tobacco (active and
passive smoking, as well as other forms of tobacco) [27–30].
There are several key actions targeting tobacco control such as
the WHO Framework Convention on Tobacco Control and the
MPOWER package of interventions (monitor tobacco use and
prevention policies; protect people from tobacco smoke; offer
help to quit tobacco use; warn about the dangers of tobacco;
enforce bans on tobacco advertising, promotion and sponsor-
ship, and; raise taxes on tobacco) [31]. Reducing air pollution
exposure results in lower CRD morbidity and mortality.
Educational interventions have not been fully studied [32].
Pulmonary rehabilitation is effective in COPD [33]. Regular
physical activity should be encouraged in these patients. In-
fluenza and pneumococcal vaccinations are recommended for
the prevention of COPD exacerbations [25].
Successful interventions in LMICs
Preventive measures reducing biomass fuel combustion were
found to reduce the risk of COPD [3, 34].
Community-wide programmes
Community-wide programmes on COPD control have been
started in many countries but definitive results are not yet
available [35].
SDB
Successful interventions in developed countries
Active education programmes on diet and exercise are an
important component of SDB management [36]. Continuous
positive airway pressure is highly effective in obstructive sleep
apnoea syndrome (OSAS) and decreases cardiovascular com-
orbidities [37, 38].
Community-wide programme
A Finnish national programme has been started for the
prevention and treatment of sleep apnoea (2002–2012) [39].
Occupational CRDs
Pneumoconiosis
Improvement in ventilation and government legislation has
dramatically reduced the prevalence of pneumoconiosis in
many countries [1] but more data are needed in LMICs.
Occupational asthma in developed countries
Control of exposure by noxious agent substitution, improve-
ment of ventilation, change in process and enclosure is effec-
tive in the primary and secondary prevention of occupational
asthma [40, 41].
Early determinants of chronic respiratory diseases
Successful interventions in developed countries
In respiratory distress syndrome of premature infants, surfac-
tant and antenatal steroids [42] have dramatically decreased
deaths. Primary prevention of allergy and asthma is still a
matter of debate, as only multifaceted interventions have
shown some efficacy [43, 44]. A Finnish national programme
associated with the Global Alliance Against Chronic Res-
piratory Diseases (GARD) has been started for the prevention
and treatment of allergy and asthma (2008–2018) [45].
Successful interventions in LMICs
Reduction of indoor air pollution exposure from biomass fuel
use is a potentially important intervention for the prevention of





Rhinitis (excluding asthma) 400 million
Sleep-disordered breathing .100 million
Other CRDs .50 million
2007 World Health Organization estimates [1]. COPD: chronic obstructive
pulmonary disease.
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acute respiratory infection in children [46, 47] but evidence for
its impact is lacking [48].
Transverse NCD prevention and control programmes with
CRD components
HCPs face considerable and diverse challenges in LMICs.
These include separate, disease-specific interventions frag-
menting and duplicating efforts, limiting resources across a
range of priorities, as well as competing with programmes
against communicable diseases. However, such transverse
programmes: 1) may face difficulties in the evaluation of their
effectiveness; 2) do not usually provide for adaptation to
national, regional, and local needs and resources, resulting in
nonfeasibility, nonsustainability or both; 3) do not usually
develop a partnership between policy makers and HCPs in the
field and, consequently, fail to transform evidence into policies
and policies into practice; and 4) do not usually develop and
implement affordable educational methods that can be
sustained in the resource-poor settings of LMICs.
There are few examples of successful programmes incorporating
several NCDs, in some cases with infectious diseases in children
and adults [49–51]. Lessons learnt from these initial efforts
confirm that such methods may be extended in many LMICs to
address priority needs in NCD prevention and management.
Models of risk factor effect and avoidance on CRDs
There is little systematically collected evidence on the overall
contribution of environmental risk factors to the global burden of
disease. WHO recently completed a comprehensive, systematic
and transparent estimate of the disease burden attributable to the
environment, and 24% of the global burden of disease was
estimated to be due to environmental risk factors [52].
The WHO Comparative Risk Assessment methodology [53]
enabled the assessment of global mortality and morbidity
resulting from exposures to selected occupational hazards in
the year 2000. Occupational risk factors were responsible for 13%
of COPD cases, 11% of asthma cases, 9% of lung cancer cases,
and 100% of pneumoconioses and mesothelioma cases [54].
Health benefits that environmental interventions could achieve
are major considerations when choosing environmental health
actions to prevent disease. WHO has released profiles of the
environmental burden of disease for 192 countries [55]. 13–37%
of the countries’ disease burdens could be prevented by
environmental improvements, resulting in a reduction of ,13
million deaths per yr [56].
For successful NCD prevention and control strategies, a focus
on individuals needs to complement population-wide strate-
gies. Strategies that focus on individuals are cost-effective only
when targeted at high-risk groups. Tools predicting an indi-
vidual’s absolute NCD risk are vital for targeting limited res-
ources in high-risk individuals who are likely to benefit the most
[57]. The WHO/International Society of Hypertension (ISH)
charts, already available, enable the prediction of the future risk
of heart attacks and strokes in people living in LMICs [57, 58].
Risk charts are also available for cancer [59].
PRIORITISED RESEARCH AGENDA FOR CRDS
Research opportunities vary between high-income countries,
where diagnostic methods and treatments are usually available,
and LMICs. The priorities should be flexible enough to
harmonise the specific needs and conditions of the countries.
Standardised methods, in particular for epidemiologic studies,
should be made available and should be tailored for LMICs. The
redefining (phenotyping) of CRDs is ongoing and will influence
the programme in coming years as well as the transition of
disease burden in different regions and climate changes.
Dissemination of the relevant information and training of
primary health care should be part of the research programme.
Five topics have been prioritised according to short-, medium-
or long-term deliverables (table 2) and depending on burden,
perceived need in LMICs, potential impact on health and gaps
in knowledge, as well as cost-effectiveness and applicability to
LMICs as follows. 1) Severe/uncontrolled asthma is a major
health problem and interventions seem to be cost-effective,
considerably reducing burden and mortality. They should be
tested in various settings and comorbidities should be con-
sidered. 2) Modelling for estimates of the impact of interven-
tions for prevention of NCD should be envisaged, and risk
charts for COPD and OSAS can be developed. 3) The impact of
reduction in obesity on the prevention of SDB should be
studied as part of the NCD prevention plan. 4) Assessment of
patterns of disease and symptoms in adults presenting to first-
level facilities in LMICs should serve as a guide to the deve-
lopment of transverse programmes. 5) Development and
evaluation of transverse (integrated) programmes of preven-
tion and care in selected LMICs with different resources and
needs employing methods used in the Practical Approach to
Lung Health (PAL) [51], Practical Approach to Lung Health
and HIV/AIDS in South Africa (PALSA Plus) [50, 60] and
other similar programmes. A dominant feature of this pro-
gramme is the strengthening of health systems through edu-
cation and the optimal use of resources.
Other interventions should be discussed. Research should be
conducted to better appreciate definition, risk factors, burden,
prevention and control, and a programme should be started
when sufficient knowledge becomes available.
TOPICS FOR FUTURE RESEARCH
Some CRDs are known to be of great importance, but further
studies are needed to fully define their burden and/or the
methods needed to be established/validated for their assess-
ment in population-based surveys in LMICs. There is a need for
operational research, better surveillance of vital statistics,
standardisation of lung function testing in LMICs and estima-
tion of costs of improving management of CRD. Once these
methods are clarified, research should start in areas including
SDB, bronchietasis and pulmonary hypertension.
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TABLE 2 Research priorities in chronic respiratory diseases (CRDs) from the public health perspective, proposed to focus on
low- and middle-income countries (LMICs) but recommended for all countries
Topic Short term Medium term Longer term
1) Severe/uncontrolled asthma
and comorbidities
To reach consensus on a universal
definition of severe/uncontrolled asthma
in adults and children with identification
of gaps in the knowledge
To develop and validate, in pilot
studies, a protocol to estimate
the prevalence, case fatality rate
and comorbidities of severe/
uncontrolled asthma
To characterise the phenotypes of
patients with severe/uncontrolled
asthma and search for specific risk
factors and comorbidities
Gaps in knowledge and gaps in
knowledge translation into policies
To estimate (and monitor annually) the number
of countries with access to
spirometry, essential medicines for
CRDs and adequate care (common
to topics 1, 3, 4 and 5)
To implement studies in LMICs to
confirm the impact of access to
ICS on morbidity and case fatality
of severe/uncontrolled asthma in
children and adults
To investigate genomics
To redefine severe asthma pheno-
types according to latest research
2) Impact of primary and
secondary prevention of CRDs
To develop models to estimate the
regional and global attributable fraction
of risk of CRD related to tobacco smoke,
solid fuel combustion, outdoor air
pollution and allergens, and the potential
impact of interventions for their reduction
To develop risk charts for COPD
and OSAS using the methodology of
WHO CVD risk charts, and to test its
usefulness as a tool to change beha-
viour of health professionals, users of
health services and the community
To review risk charts and assess
impact of their adoption on tangible
health outcomes
To develop models to estimate the impact
of healthy diet and physical activity on
prevention and control of obesity and its
major comorbidities, such as CVDs,
type II diabetes and SDB
To develop and validate, in
pilot studies, simple protocols
(including questionnaires and
spirometry) to assess the CRD risks
To develop models to estimate the impact of
early detection of occupational CRDs and
subsequent intervention on the prevention of
disability due to occupational CRDs
3) Effectiveness of integrated
prevention and management
of chronic diseases in PHC in
low-resource settings
To investigate the feasibility, effectiveness and
affordability of integrated prevention and man-
agement strategies for CRDs, CVDs, diabetes
and other priority diseases in PHC in pilot
countries. Based on PAL, PALSA Plus, IMAI,
IMCI and other programmes
To assess CRD burden on
emergency services and
PHC facilities
To evaluate benefit of large-scale
community education campaigns and
community participation in the
prevention and control of NCDs
(including CRDs) in different cultural
and economic settings
To investigate the outcomes of a tailored
syndromic approach to case management of
chronic diseases in PHC by trained nurses with
the supervision of physicians in pilot countries
using an implementation plan based on PAL,
PALSA Plus, IMAI, IMCI and other programmes
To develop methods for
measurement of the impact of the
interventions (e.g. indicators and
outcomes for audit and pragmatic
randomised controlled trials)
To estimate (and monitor annually) the number
of countries with access to spirometry, essential
medicines for CRDs and adequate care
(common to topics 1, 3, 4 and 5)
4) COPD and comorbidities To reach consensus on a universal definition of
COPD, COPD exacerbations and risk factors for
exacerbations, and to address gaps in
knowledge to understand mechanisms
of exacerbations
Surveys to assess the COPD
prevalence, risk factors and
comorbidities (CVDs, cancer and
diabetes) in population based
studies (BOLD initiative)
Evaluate benefits of treatment on
both COPD and all NCDs over
treatment of individual diseases,
PROs, and specific and general
health outcomes, as well as in costs
Planning management of a
person with COPD and
concomitant comorbidities
(CVDs, diabetes and others)
To propose essential PROs acceptable
in all countries
To estimate (and monitor annually) the number
of countries with access to spirometry, essential
medicines for CRDs and adequate care (com-
mon to topics 1, 3, 4 and 5)
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Universitaire de Béni-Messous, Algiers, Algeria), D. Dumitrascu
(University of Medicine and Pharmacy IULIU HATIEGANU, Cluj-
Napoca, Romania), D. Enarson (International Union Against
Tuberculosis and Lung Disease, Paris, France), J.L. Eiselé (ERS,
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awareness and demand to health
services, lack of access to
proper care
Develop methodology for a survey in
LMICs to study prevalence of CRD and
high risk patients in children
,5 yrs of age
To develop and validate strategies
for the management of acute
respiratory diseases and asthma in
LMICs for children ,5 yrs of age
Develop and evaluate efficacy of
preventive interventions worldwide
and in LMICs
To estimate (and monitor annually) the number
of countries with access to spirometry, essential
medicines for CRDs and adequate care
(common to topics 1, 3, 4 and 5)
A global fund for CRD research in LMICs should be developed. PHC: primary health care; COPD: chronic obstructive pulmonary disease; OSAS: obstructive sleep apnoea
syndrome; WHO: World Health Organization; CVD: cardiovascular disease; PAL: Practical Approach to Lung Health; PALSA Plus: Practical Approach to Lung Health and
HIV/AIDS in South Africa; IMAI: Integrated Management of Adolescent and Adult Illnesses; IMCI: Intergrated Management of Childhood Illnesses; NCD: noncommunicable
disease; PRO: patients’ reported outcome; BOLD: Burden of Obstructive Lung Disease; ICS: inhaled corticosteroids; SDB: sleep-disordered breathing.
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